The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone

Sponsor
Chinese PLA General Hospital
Study ID
NCT03215407
Phase
PHASE4
Status
Unknown

Conditions

  • Rheumatoid Arthritis of Knee

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Intra-articular Tocilizumab — DRUG
    Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
  • Intra-articular Compound Betamethasone — DRUG
    Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection

Study Details

Aim: Comparing the efficacy and safety of intra-articular injection of tocilizumab and compound betamethasone. Study design: A randomized, single-blind, parallel controlled and one center trial design. Sample size: 60 cases. Study content: Patients who meet inclusive criteria will be randomly divided into tocilizumab group and compound betamethasone group. In the baseline period, the investigators will collect patients' general information, disease information, disease activity score, laboratory results and images of articular ultrasound. After 4 weeks of injection, patients will be asked to come back, and their disease information, disease activity score, laboratory results as well as images of articular ultrasound will be collected. Finally, these data will be sorted and analyzed. Hypothesis: The efficacy and safety of intra-articular injection of tocilizumab is better than that of compound betamethasone.

Key Dates

Start date
Aug 1, 2017
Status verified
Jul 2017
Primary completion
Dec 12, 2017
Completion
Mar 3, 2018

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intra-articular Tocilizumab
    Tocilizumab, solution, 80mg intra-articular.
  • Active Comparator: Intra-articular Compound Betamethasone
    Compound betamethasone, solution, 14mg intra-articular

Primary Outcome Measure

change from OMERACT-EULAR composite PDUS synovitis score at 4 weeks [ Time Frame: 0 and 4 weeks ]